Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma

Piñero, Federico; Tanno, Mario; Soteras, Gabriel Aballay; Baña, Matías Tisi; Dirchwolf, Melisa; Fassio, E; Ruf, Andrés E.; Mengarelli, Silvia; Borzi, Silvia; Fernández, Nora; Ridruejo, Ezequiel; Descalzi, Valeria; Anders, Margarita; Mazzolini, Guillermo; Reggiardo, Virginia; Marciano, Sebastián; Perazzo, Florencia; Spina, Juan Carlos; McCormack, Lucas; Maraschio, Martín; Lagues, Cecilia; Gadano, Adrián; Villamil, Federico; Silva, Marcelo; Cairo, Fernando; Ameigeiras, Beatriz

doi:10.1016/j.aohep.2020.06.003

Cited by 12 publications

(9 citation statements)

References 316 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the early development of HCC in Latin American patients with HBV, it might be argued that the age for surveillance should probably be anticipated in relation to that of individuals of European ancestry and closer to what is recommended for Asian or African individuals [32] . In this context, the Brazilian Society of Hepatology, for instance, recommends surveillance for patients with HBV who have cirrhosis or other risk factors for HCC, such as Asian or African ethnicity, age over 40 years for men or over 50 years for women, family history of HCC in a first-degree relative, coinfection with HCV or HIV and association with NAFLD [46] . Moreover, other methods should be investigated to improve surveillance and early detection of HCC.…”

Section: Target Populationmentioning

confidence: 99%

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Anugwom¹,

Allaire²,

Akbar³

et al. 2021

View full text Add to dashboard Cite

Hepatitis B infection (HBV) is one of the most common causes of hepatocellular carcinoma (HCC) worldwide. The age of occurrence, prognosis and incidence vary dramatically depending on the region of the world. This geographic variation is largely dependent on the contrasting incidence of HBV, age of transmission of the virus, the timing of integration into the human genome, and different HBV genotypes, as well as environmental factors. It results in a wide difference in viral interaction with the immune system, genomic modulation and the consequent development of HCC in an individual. In this review, we describe many factors implicated in HCC development, provide insight regarding at-risk populations and explain societal recommendations for HCC surveillance in persons living with HBV in different continents of the world.

show abstract

Section: Target Populationmentioning

confidence: 99%

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Anugwom¹,

Allaire²,

Akbar³

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Study inclusion criteria were adult patients (>17 years) listed for LT because of HCC or patients listed for liver decompensation who develop HCC while on WL. HCC was diagnosed according to international and national guidelines from January 1, 2012 to December 31, 2018 16–18 . Patients evaluated but not enlisted for a liver transplant because of tumour extension (macrovascular invasion, extrahepatic disease or ganglionic metastasis) were excluded, as also those with incidental findings of HCC at the explant pathological examination.…”

Section: Methodsmentioning

confidence: 99%

“…Results: HCC dropout rate was significantly higher in patients beyond (24% [95% CI [16][17][18][19][20][21][22][23][24][25][26][27][28]) compared to those within Milan criteria (8% [95% IC 5%-12%]; p < .0001), with a SHR of 3.01 [95% CI 2.03-4.47]), adjusted for waiting list time and bridging therapies (c-index 0.63 [95% CI 0.57; 0.69). HCC dropout rates were higher in patients with AFP scores >2 (adjusted SHR of 3.17 [CI 2.13-4.71]), c-index of 0.71 (95% CI 0.65-0.77; p = .09 vs Milan).…”

Section: Introductionmentioning

confidence: 99%

Performance of pre‐transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout

Piñero

Thompson²,

Boin

et al. 2022

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The occurrence and progression of HCC are related to many factors (HBV infection, eating habits and drinking, etc.) (Piñero et al, 2020). Because there are no nerves in the liver tissue, most cancers have entered the advanced stage when patients feel pain and other discomfort.…”

Section: Introductionmentioning

confidence: 99%

A novel prognostic target-gene signature and nomogram based on an integrated bioinformatics analysis in hepatocellular carcinoma

Xu¹,

Wu²,

GONG³

et al. 2022

Biocell

View full text Add to dashboard Cite

There is currently no effective solution to the problem of poor prognosis and recurrence of HCC. The technology of immunotherapy and prognosis of genetic material has made continuous progress in recent years. In the study, a 5-gene signature was established for the prognosis of HCC through biological information, and the immune infiltration of HCC patients was studied. After studied HCC patients' immune infiltration, the paper screened the differential target genes of miR-126-3p in HCC downloaded from TCGA database, and uses WGCNA method to select the modular genes highly relevant to M2 macrophage. Then we use LASSO and COX regression analysis technology to establish the 5-gene signature. The nomogram is established by combining the prognostic score and clinical phenotype. Cibersort was empolyed to observe the immune infiltration in HCC patients. We revealed the biological pathways of HCC-related genes through GSEA and Metascape. The bioinformatics analysis of 2495 differential target genes finally constructed a 5-gene signature with a reliable prognostic ability (CDCA8, SLC41A3, PPM1G, TCOF1, GRPEL2). The combination of prognostic score and AJCC_Stage resulted in a more reliable prognosis ability. At the same time, 10 immune cells that are differentially expressed in HCC patients were also found. 8 GSEA pathways related to the prognosis were found. In the study, a reliable 5-gene signature was established based on the differential target gene of miR-126-3p to study the immune infiltration in HCC patients. It provides help for HCC-related prognosis research and immunotherapy.

show abstract

Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma

Cited by 12 publications

References 316 publications

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Performance of pre‐transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout

A novel prognostic target-gene signature and nomogram based on an integrated bioinformatics analysis in hepatocellular carcinoma

Contact Info

Product

Resources

About